- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03420092
A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
A Randomized, 6-period, 6-treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Relative Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, HA1 3UJ
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent before any study specific procedures.
- Healthy male and/or female subjects aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non childbearing potential, confirmed at screening by fulfilling one of the following criteria 3.1. Postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the postmenopausal range.
3.2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.
- Provision of signed, written and dated informed consent for optional genetic/biomarker research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this protocol.
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at-risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
- History or presence of gastrointestinal (GI), hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
- Participants with any special dietary restrictions such as subjects that are lactose intolerant or are vegetarians/vegans.
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
- Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis results, at screening and/or admission to the study unit as judged by the PI.
- Any clinically significant abnormal findings in vital signs at screening, as judged by the PI.
- Any clinically significant abnormalities on 12-lead ECG at screening and/or admission to the study unit, as judged by the PI.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.
- Known of suspected Gilbert's syndrome and known or suspected history of drug abuse, as judged by the PI.
Has received another new chemical or biological entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.
Note: Participants consented and screened, but not randomized in this study or a previous phase I study, are not excluded.
- Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months before screening.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD5718.
- Current smokers or those who have smoked or used nicotine products (including e-cigarettes) within the 3 months before screening.
- Positive screen for drugs of abuse or cotinine (screening only) at screening or on each admission to the study center or positive screen for alcohol on each admission to the study center.
- Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks before the first administration of IMP.
- Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks before the first administration of IMP or longer if the medication has a long half life.
- Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the PI.
- Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.
- Subjects who have previously received AZD5718.
- Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.
- Vulnerable subjects, e.g., kept in detention, protected adults under guardianship.
- Non-leukocyte depleted whole blood transfusion within 120 days of the date of the genetic sample collection or previous bone marrow transplant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
The participant will be administered with Form 1 of AZD5718 tablets with an overnight fast of at least 10 hours.
|
The participants will be dosed with Form 1 of AZD5718 following an overnight fast of at least 10 hours.
|
Experimental: Treatment B
The participant will be administered with Form 2 of AZD5718 tablets with an overnight fast of at least 10 hours.
|
The participants will be dosed with Form 2 of AZD5718 following an overnight fast of at least 10 hours.
|
Experimental: Treatment C
The participant will be administered with Form 3 of AZD5718 tablets with an overnight fast of at least 10 hours.
|
The participants will be dosed with Form 3 of AZD5718 following an overnight fast of at least 10 hours.
|
Experimental: Treatment D
The participant will be administered with Form 4 of AZD5718 tablets with an overnight fast of at least 10 hours.
|
The participants will be dosed with Form 4 of AZD5718 following an overnight fast of at least 10 hours.
|
Experimental: Treatment E
The participant will be administered with Form 5 of AZD5718 tablets with an overnight fast of at least 10 hours.
|
The participants will be dosed with Form 5 of AZD5718 following an overnight fast of at least 10 hours.
|
Experimental: Treatment F
The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
|
The participant will be administered with selected form (one of Form 2-5) of AZD5718 tablets 30 minutes after start of the meal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under plasma concentration-time curve (AUC) of AZD5718
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the pharmacokinetics (PK) parameter AUC to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
AUC from time zero to time of last quantifiable concentration (AUC[0-t]) of AZD5718
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the PK parameter AUC(0-t)to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
Observed maximum plasma concentration (Cmax) of AZD5718
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the PK parameter Cmax to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
Observed plasma concentration at 24 hours post dose (C24) of AZD5718
Time Frame: 24 hour post dose
|
To assess the PK parameter C24 to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
24 hour post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of AZD5718 in fed and fasted conditions
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the ratio of Cmax of a selected AZD5718 formulation when administered in fed and fasted conditions and relative bioavailability of the tested formulations.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
C24 of AZD5718 in fed and fasted conditions
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the ratio of C24 of a selected AZD5718 formulation when administered in fed and fasted conditions and relative bioavailability of the tested formulations.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
AUC(0-t) of AZD5718 in fed and fasted conditions
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the ratio of AUC(0-t) of a selected AZD5718 formulation when administered in fed and fasted conditions and relative bioavailability of the tested formulations.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
AUC of AZD5718 in fed and fasted conditions
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the ratio of AUC of a selected AZD5718 formulation when administered in fed and fasted conditions and relative bioavailability of the tested formulations.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
Number of participants with adverse events
Time Frame: From randomization throughout the treatment period (Day 1 to 3) and follow-up Visit (Day 5 to 7) assessed maximum upto 6 weeks.
|
All adverse events will be coded using MedDRA vocabulary, and will be listed for each subject.
|
From randomization throughout the treatment period (Day 1 to 3) and follow-up Visit (Day 5 to 7) assessed maximum upto 6 weeks.
|
Assessment of systolic blood pressure
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
To assess the systolic blood pressure as a criteria of safety and tolerability.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
Assessment of diastolic blood pressure
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
To assess the Diastolic blood pressure as a criteria of safety and tolerability.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
Assessment of pulse rate
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
To assess Pulse rate as a criteria of safety and tolerability.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
Assessment of 12-lead electrocardiogram (ECG)
Time Frame: At screening (From Day -28 to Day -2 - Part 1); 5 to 7 days post final dose (Part 2).
|
To assess the ECG as a criteria of safety and tolerability.
A 10 second 12 lead ECG will be obtained after 10 minutes supine rest.
|
At screening (From Day -28 to Day -2 - Part 1); 5 to 7 days post final dose (Part 2).
|
Assessment of physical examination
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
Assessment of physical examinations will include an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose].
|
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz) of AZD5718
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess PK parameter t½λz to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
Time to reach maximum observed plasma concentration (Tmax) of AZD5718
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the PK parameter Tmax to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of AZD5718
Time Frame: At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
To assess the PK parameter CL/F to evaluate the relative bioavailability of different formulations of AZD5718 and compare with the formulation (Form 1 of AZD5718 tablets) used in the Phase 2a clinical study.
|
At pre dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 36 and 48 hours post dose.
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (Hematology)- white blood cell (WBC) count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of WBC count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- red blood cell (RBC) count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of RBC count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- haemoglobin (HB)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of HB.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- hematocrit (HCT)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of HCT.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- platelets
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of platelets.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- reticulocytes absolute count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of reticulocytes absolute count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- mean corpuscular hemoglobin (MCH)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of MCH.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (hematology)- mean corpuscular hemoglobin concentration (MCHC)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of MCHC.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- creatinine
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of creatinine.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- creatine kinase
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of creatine kinase.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- total bilirubin
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of total bilirubin.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- unconjugated bilirubin
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of unconjugated bilirubin.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- alkaline phosphatase
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of alkaline phosphatase.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- aspartate aminotransferase (AST)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of AST.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- gamma glutamyl transpeptidase (GGT)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of GGT.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- albumin
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of albumin.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- potassium
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of potassium.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- sodium
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of sodium.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (clinical chemistry)- calcium
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of calcium.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- C-reactive protein
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of C-reactive protein.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical Laboratory evaluations (clinical chemistry)- urea
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of urea.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- phosphate
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of phosphate.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- glucose (fasting)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of glucose (fasting).
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations- urinalysis (blood)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of urinalysis (blood).
If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, white blood cell [WBC], casts [cellular, granular, hyaline]).
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations- urinalysis (glucose)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of urinalysis (glucose).
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Mean corpuscular volume (MCV)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of MCV.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- Alanine aminotransferase (ALT)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of ALT
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (clinical chemistry)- Thyroxine 4 (T4)
Time Frame: At screening (From Day -28 to Day-2)
|
Safety and tolerability of AZD5718 by assessment of T4.
|
At screening (From Day -28 to Day-2)
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations(clinical chemistry)- Thyroid stimulating hormone (TSH)
Time Frame: At screening (From Day -28 to Day-2)
|
Safety and tolerability of AZD5718 by assessment of TSH.
|
At screening (From Day -28 to Day-2)
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations(clinical chemistry)- Follicle stimulating hormone (FSH)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of FSH in female participants.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Neutrophils absolute count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of neutrophils absolute count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Lymphocytes absolute count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of lymphocytes absolute count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Monocytes absolute count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of monocytes absolute count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Basophils absolute count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of basophils absolute count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations- urinalysis (protein)
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of urinalysis (protein).
If urinalysis is positive for protein, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of clinical laboratory evaluations (hematology)- Eosinophils absolute count
Time Frame: [Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Safety and tolerability of AZD5718 by assessment of eosinophils absolute count.
|
[Part 1 - At screening (From Day -28 to Day-2); Treatment period 1 (Day-1), Treatment period 1 to 5 (Day 1 to 3)] and [Part 2- At Day-1, Day 1 to 3, 5 to 7 days post final dose]
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pablo Forte Soto, MD, Parexel Early Phase Clinical Unit London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D7550C00005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on Form 1 of AZD5718 tablets
-
AstraZenecaCompletedCardiovascular Disease | Healthy Male SubjectsUnited Kingdom
-
Sironax USA, Inc.CompletedCorona Virus InfectionPakistan, United States, Mexico
-
AbbVieCompletedHealthy VolunteerUnited States
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedImprove the Informed Consent ProcessUnited States
-
Novartis PharmaceuticalsCompletedPsoriasisBelgium, Russian Federation, Germany, Spain, United States, Turkey, United Kingdom, Poland, Latvia, Iceland, Canada
-
Assiut UniversityNot yet recruitingChild Mental Disorder | Child Behavior Disorders | Adolescent BehaviourEgypt
-
Radicle ScienceActive, not recruiting
-
Mylan Pharmaceuticals IncCompletedHealthyUnited States
-
Radicle ScienceActive, not recruitingCognitive FunctionUnited States
-
Sinew Pharma Inc.Completed